Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. - Wikidata - wikimedia - TriplyDB

Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18.

Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18.

http://www.wikidata.org/entity/Q33691730

about

Clinical usefulness of novel serum and imaging biomarkers in risk stratification of patients with stable angina The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture.The vascular effects of infection in Pediatric Stroke (VIPS) Study.Oxidative risk for atherothrombotic cardiovascular disease.Association of myeloperoxidase with total and cardiovascular mortality in individuals undergoing coronary angiography--the LURIC study.Myeloperoxidase levels predicts angiographic severity of coronary artery disease in patients with chronic stable angina.Comprehensive peroxidase-based hematologic profiling for the prediction of 1-year myocardial infarction and death.Plasma concentrations of soluble CD40 ligand in smokers with acute myocardial infarction: a pilot study.A low-frequency variant in MAPK14 provides mechanistic evidence of a link with myeloperoxidase: a prognostic cardiovascular risk marker.Reactive oxygen species in cardiovascular disease.Role of oxidative stress in disease progression in Stage B, a pre-cursor of heart failure.Soluble CD40 Ligand in Aspirin-Treated Patients Undergoing Cardiac Catheterization Risk prediction with serial myeloperoxidase monitoring in patients with acute chest pain.A Synergistic Role of Myeloperoxidase and High Sensitivity Troponin T in the Early Diagnosis of Acute Coronary Syndrome.Identification of myocardial injury in the emergency setting.Multimarker Risk Stratification in Patients With Acute Myocardial Infarction Altered gene expression in T-cell receptor signalling in peripheral blood leucocytes in acute coronary syndrome predicts secondary coronary events.Emerging families of biomarkers for coronary artery disease: inflammatory mediators Functional measures, inflammatory markers and endothelin-1 as predictors of 360-day survival in centenarians.The role of myeloperoxidase (MPO) for prognostic evaluation in sensitive cardiac troponin I negative chest pain patients in the emergency department Myeloperoxidase, modified lipoproteins, and atherogenesis.Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution.Role of myeloperoxidase in cardiology.Tumor necrosis factor superfamily molecules in acute coronary syndromes.The CD40-CD40L system in cardiovascular disease.Current role of myeloperoxidase in routine clinical practice.Gender-specific differences in biomarkers responses to acute coronary syndromes and revascularization procedures.Cardiogenic shock in ACS. Part 2: Role of mechanical circulatory support.Diagnosis of subclinical coronary atherosclerosis: challenges and insight.Selection and timing for invasive therapy in non-ST-segment-elevation acute coronary syndrome.Is there a clinical role for oxidative stress biomarkers in atherosclerotic diseases?Novel Risk Stratification Assays for Acute Coronary Syndrome.Sequential analysis of myeloperoxidase for prediction of adverse events after suspected acute coronary ischemia.Coronary leukocyte activation in relation to progression of coronary artery disease.The Time Course of Markers of Neutrophil Extracellular Traps in Patients Undergoing Revascularisation for Acute Myocardial Infarction or Stable Angina Pectoris.Leukocyte counts, myeloperoxidase, and pregnancy-associated plasma protein a as biomarkers for cardiovascular disease: towards a multi-biomarker approach.A defect in Δ6 and Δ5 desaturases may be a factor in the initiation and progression of insulin resistance, the metabolic syndrome and ischemic heart disease in South Asians Comparison of the Effects of Enoxaparin and Heparin on Inflammatory Biomarkers in Patients with ST-segment Elevated Myocardial Infarction: A prospective Open Label Pilot Clinical Trial.Mid-regional pro-atrial natriuretic peptide as a prognostic marker for all-cause mortality in patients with symptomatic coronary artery disease.Preconditioning potential of purmorphamine: a hedgehog activator against ischaemic reperfusion injury in ovariectomised rat heart.

P2860

Q26859111-3ADB4732-EBF4-4957-B7AF-B3ABB4303103 Q30240734-D6A16833-01BB-4102-A3A6-FF84B72D942C Q30425204-EE9A73D4-E634-4EFF-BEC9-1ABFE4D28289 Q33554184-AF9EB2E7-342C-49BA-AF7E-95E761C43D26 Q33709886-49220F2C-7ECA-4200-A4CF-0ED13FD225A7 Q34072878-5E005BCD-63E4-4820-AF2E-5CC633E4AD1C Q34460042-0FC46E9D-BC30-40C9-8E88-15220298566D Q34647991-05E01903-3D9B-4623-90AA-6691AD0525B7 Q35026376-1A66F966-BC5E-41D1-86FE-3D45418EC83A Q35165194-39B19B9F-10D3-4D4C-8AA9-BD4FEBFD1E4D Q35581462-EF14BE0F-B3DF-4311-8DAE-0B13298B5830 Q35735264-9E602BC5-B441-47CA-93B0-27DA4C1CE1E1 Q35909357-D174C876-A1EA-414B-8F1C-C734EBB2F390 Q36515746-1D3A38FC-9186-406A-9F27-C6D6E8D7A13A Q36601679-3ABBBF8C-CCA9-42BF-9B06-70D11F43F944 Q36956650-C5BCAE70-F497-4CB9-85CC-2EEB11F89C47 Q37063521-5AAE03DA-A955-472E-BFF3-48ABCA8A14D4 Q37115819-9D4B7331-A040-4844-B85C-7553F1FD6618 Q37219271-880D92F6-7947-41F1-B181-5EAE5F557742 Q37291868-B9D3523A-1569-40A1-8201-7E375EA26775 Q37353408-04DFA229-E35D-4833-8C6F-4A7B4C1175F9 Q37379631-743E2383-57CD-44C5-A902-189EE0F467B3 Q37798811-A701B917-81C6-404D-90C8-D699E367B7BA Q37805514-91BF4E87-E74D-4D1F-9AC1-1F3D9F1C0CA5 Q37829738-C2C84B3E-80D1-444D-8E93-5E6C3A6261EE Q37859787-F78E3081-006D-4883-B3D5-814D807876EA Q37919535-C922A506-7DD7-4609-8DC8-B16F8235B4C7 Q37974559-DF306C56-9007-467F-9940-50813CB8F269 Q38089811-56B4E02C-E676-49A8-99FD-196F295D2BD2 Q38097508-CDECD602-3E63-4074-889F-00296C663E0D Q38140700-852C4CA3-DEDF-4C70-BA71-F901E4E7EB82 Q38666324-44EE0B55-E747-4ECD-87E9-F480EE842DED Q39097080-A84C00E0-EA6F-49D3-9B9D-427042315ED7 Q40035861-43902F25-BE47-4F29-8D24-04593187FA76 Q40248462-4635A909-B966-469A-9772-A0FA25167C16 Q41216845-A6C30F02-D709-47FB-B898-44EF8FDC0756 Q41722248-F856F5A3-9CE7-435F-BDD3-031DABD5FB56 Q42867694-CA18BF69-3702-4941-8CF3-3AAD36E924A5 Q45370584-7B4A383E-1E50-4348-AAC5-CED552CE9602 Q47600094-1E5EE476-092F-4BBA-85E2-46D2ADA77A33

P2860

Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18.

http://www.wikidata.org/entity/Q33691730

description

2008 nî lūn-bûn

@nan

2008 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մարտին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Concurrent evaluation of novel ...... mic events in TACTICS-TIMI 18.

@ast

Concurrent evaluation of novel ...... mic events in TACTICS-TIMI 18.

@en

type

label

Concurrent evaluation of novel ...... mic events in TACTICS-TIMI 18.

@ast

Concurrent evaluation of novel ...... mic events in TACTICS-TIMI 18.

@en

prefLabel

Concurrent evaluation of novel ...... mic events in TACTICS-TIMI 18.

@ast

Concurrent evaluation of novel ...... mic events in TACTICS-TIMI 18.

@en

P1433

Q33691730-6A176F21-7D71-4B93-A816-EEC829919B70

P1476

Q33691730-E0F17FA0-A625-4E99-B2F9-18AE1FFCCBB7

P2093

Q33691730-08C974C1-43FD-4356-BAB2-C7CB7C47E553

Q33691730-1E281017-352C-4D0D-ACA3-A6E9C5ECCF8A

Q33691730-27515E93-0396-43B8-80D6-E544AABBE2FA

Q33691730-3724BDE6-62BB-4FA2-A05F-925C2EB25507

Q33691730-3EBDA44A-691F-4F0A-B596-B2A8F0A23F60

Q33691730-7213BA63-EA7D-4DA9-B5CE-215F043EA511

Q33691730-77175A03-841F-42E2-AF49-094CA2E49917

Q33691730-CA97F3A7-2417-4C0F-A109-B4C55212CF6E

Q33691730-D2953FDC-016C-4D99-9C0A-90A918326C8B

P2860

Q33691730-0418A01B-3233-4DB6-8E95-C269404966C8

Q33691730-077D0C6A-1ECB-4033-971B-244720829046

Q33691730-11119732-585D-40E0-A79E-DA09D0A443EF

Q33691730-307D306F-1B32-4555-8E83-749930CBCEEA

Q33691730-3C00F0D2-29AC-4BB5-A392-35B5A93421C5

Q33691730-4601FC41-0486-4E99-B424-9035FFF3385A

Q33691730-49FABD81-15AF-4B32-BFCA-CB4AD4D4EB1E

Q33691730-4F7DA8D7-35D7-497C-9CE1-7205875A22D3

Q33691730-5ACD1591-D998-426F-9BCC-AAE6B01BB36A

Q33691730-68547496-C001-4A01-9773-3F57F22ACE34

P304

Q33691730-341C452A-35D8-46F1-BFD3-959A0D76EE2B

P31

Q33691730-0D694EDF-74A7-40A2-B85A-4D7DA9EA4003

P356

Q33691730-7357027D-F385-4709-9EF2-D077E6D145A8

P433

Q33691730-9927F64A-B9E1-4DEC-9251-515125B15C4A

P478

Q33691730-F7C8F47C-80FE-4F88-A346-43ECF6402EFC

P577

Q33691730-A9798D41-3D0F-42FE-B99A-CDA85C04C6A2

P5875

Q33691730-1CDCD298-79A8-4D94-80B6-118DCD397030

P698

Q33691730-F9D1C542-07E6-4FFB-A97C-E911CEE63E87

P921

Q33691730-97C5C6B1-1778-4EAB-84D6-C9D7C0E76B9B

P932

Q33691730-F0B7F600-141A-4D41-AEFA-98CC63CB2514

P356

P1433

European Heart Journal

P1476

Concurrent evaluation of novel ...... mic events in TACTICS-TIMI 18.

@en

P2093

Christian T Ruff

http://www.w3.org/2001/XMLSchema#string

Christopher P Cannon

http://www.w3.org/2001/XMLSchema#string

David A Morrow

http://www.w3.org/2001/XMLSchema#string

James A de Lemos

http://www.w3.org/2001/XMLSchema#string

Marc S Sabatine

http://www.w3.org/2001/XMLSchema#string

Marie-Luise Brennan

http://www.w3.org/2001/XMLSchema#string

Nader Rifai

http://www.w3.org/2001/XMLSchema#string

Sabina A Murphy

http://www.w3.org/2001/XMLSchema#string

Stanley L Hazen

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban

Nitric oxide is a physiological substrate for mammalian peroxidases

Myeloperoxidase and its contributory role in inflammatory vascular disease.

Myeloperoxidase-generated oxidants and atherosclerosis.

Prognostic value of myeloperoxidase in patients with chest pain.

Myeloperoxidase and cardiovascular disease.

Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease.

The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport.

Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease.

Influence of sample type and storage conditions on soluble CD40 ligand assessment.

P304

1096-1102

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHN071

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2008-03-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5511951

http://www.w3.org/2001/XMLSchema#string

P698

18339606

http://www.w3.org/2001/XMLSchema#string

P921

P932

2829435

http://www.w3.org/2001/XMLSchema#string